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Objectives. The aim of this study was to investigate if hyperhomocysteinaemia is a contributive risk factor for the pathogenesis and
the activity of Behc ¸et’s disease (BD). Design and Methods. Fifty four patients fullﬁling the criteria of the International Study Group
for BD were enrolled. Fifty healthy volunteers matched for age and sex with the BD group were included as a negative control
group. Patients, with any condition that might aﬀect plasma homocysteine concentration, were excluded. Results. Mean serum
homocysteine concentration was signiﬁcantly higher in patients with BD than in the healthy controls (P<. 001), in patients with
active disease (P = .04), and in masculine gender (P = .05). There was no signiﬁcant diﬀerence between homocysteine level and
clinical involvement. Conclusions. We demonstrated that plasma total homocysteine level (tHcy) is increased in BD and correlated
with disease activity. No association was found between homocysteine levels and clinical involvement.
1.Introduction
Behc ¸et’s disease (BD) is a systemic inﬂammatory vasculitis
with unknown etiology, which typically presents with rec-
urrent orogenital ulceration, uveitis, and erythema no-
dosum. Other involvement may characterise the course of
the disease: articular, vascular, central nervous system, and
gastrointestinal involvements [1]. Thrombophlebitis, deep
vein thrombosis, arterial obstruction, and aneurysms are the
more frequent vascular damage in BD [2].
Vascular endothelial dysfunction represents the major
pathogenesis abnormalities in BD. This was demonstrated
by the reports of elevated serum concentrations of von
Willebrand factor, plasminogen activator inhibitor-1, and
thrombomodulin in patients with BD [3, 4].
Evidence from recent studies suggests that activated
leukocytes may contribute to vascular injury in BD. Concen-
tration of circulating pro-oxidants and lipid peroxidations
products are elevated in BD [5].
Homocysteine (Hcy) is a sulfur-containing amino acid
produced during the metabolism of the essential amino
acid methionine in all cells through the normal methylation
process. High levels are reported in the course of diabetes
mellitus, hyperlipidaemia, end-stage renal failure, psoriasis,
and inﬂammatory bowel disease [6–9]; it may also occur due
to vitamin B 12 or folate deﬁciency [10] or secondary to
t r e a t m e n tw i t hs o m ed r u g s ,s u c ha sM e t h o t r e x a t e[ 11].
In the other hand, hyperhomocysteinaemia (HHCY)
may cause lipid peroxidation, impaired vasomotor regula-
tion, prothrombotic surface, and, therefore, vascular endo-
thelial injury and atherothrombogenesis.
The exactmechanisms linking homocysteine toendothe-
lial disfunction are still unknown. Retrospective and pros-
pective studies support an association between HHCY and
increasing risk of cardiovascular disease, such as coronary
arterial disease, cerebrovascular disease, and venous and
arterial thrombosis [12].
During the last decade, and according to a limited num-
ber of studies, HHCY is now assumed to be an independent
risk factor for venous thrombosis [13, 14]a n df o ro c c u l a r
involvement in BD [15].
The major studies showed that vitamin supplementation
with Vitamin B 12, Vitamin B 6, and/or acid folic was asso-
ciated in a decrease in Hcy levels.
The aim of this study was to investigate whether HHCY
is a risk factor for the development of activation in BD.
2.MaterialandMethods
2.1. Methods. Fifty four patients (34 men and 20 women;
mean age 31.12±8.9 years) with BD according to the criteria2 Biochemistry Research International
Table 1: Cumulative clinical characteristics of patients with
Behc ¸et’s disease.
N Percent
Oral ulceration 54 100
Genital ulceration 49 90
Papulopustular eruption 46 85.2
Pathergy positivity 18 41.9
Arthritis 8 14.8
Uveitis 20 37
Retinal vasculitis 15 27.7
Vascular involvement 21 38.8
Deep vein thrombosis 15 27.7
Arterial aneurysm 4 7
Pulmonary embolism 7 13
Central nervous system involvement 20 37
Table 2: Demographic data (mean ± SD).
BD (n = 54) Healthy controls (n = 50)
Age (years) 31.12 ±8.93 7 .38 ±10.3
Male/Female 34/20 21/29
of the International Study Group for Behc ¸et’s disease and 50
matched healthy volunteers (21 men and 29 women; mean
age37.38±10.3years)wereenrolledinthisprospectivestudy.
The detailed clinical characteristics were recorded for each
patient.
The exclusion criteria were diabetes mellitus, psoriasis,
chronic hepatitis, chronic alcoholism, renal failure, and
pregnancy. Patients were considered active according to the
clinician’s impression and in the case of the existence of two
or more symptoms with worsening of clinical symptoms and
lack of wellbeing at the time of the study.
2.2. Measurement of Homocysteine. The blood samples
were collected in ethylenediaminetetraacetate (EDTA)—
containing tubes after 12h of fasting; they were kept in on
ice in order to prevent homocysteine formation and leakage
fromerythrocytes,andwerecentrifugedimmediatelyat2000
× g for 10 minute at room temperature. Hcy was measured
by high-performance liquid chromatography. HHCY was
deﬁned as a serum t-Hcy level > 15μmol/L.
2.3. Statistical Analysis. SPSS for Windows version 10.0 was
used to analyse the data. In the statistical evaluation of the
data, the independent samples t-test (Student’s t-test) was
used to compare the mean’s of the two groups. Correlation
analysis was performed with the Pearson correlation test P<
.05 was accepted as signiﬁcant (conﬁdence interval = 95%).
3. Results
The cumulative clinical characteristics of BD patients are
shown in Table 1. Demographic data of all groups are
Table 3: Serum homocysteine concentration.
Groups Homocysteine concentration (μmol/L)
Mean ± S.D (min−max)
BD group (n = 54) 18.07 ±8.9a
Healthy group (n = 50) 11.2 ±6.5
Active group (n = 17) 20.7 ±8b
Inactive Group (n = 37) 16.6 ±6.5
aHigher than in the healthy group; P<. 01.
bHigher than in inactive group; P = .05.
summarised in Table 2. The mean serum Hcy concentrations
in each group are shown in Table 3.
HHCY was signiﬁcantly higher in BD patients than in
controls (55.5% versus 8%; P<. 0 1 )a n di na c t i v ep a t i e n t s
than in inactive (56% versus 43%; P = .05). No signiﬁcant
correlation was found between serum Hcy concentration
and clinical features such as thrombotic events (P = .5),
u v e i t i s( 0 . 0 8 ) ,r e t i n a lv a s c u l i t i s( P = .06), and neurological
involvement (P = .4). HHCY was signiﬁcantly higher in
patients with arthritis: 87.5% versus 52.17%; P = .05.
4. Discussion
BD is a vasculitic systemic syndrome with endothelial
dysfunction [3, 4]. The mechanism of vascular involvement
hasnotyetbeenclearlydelineated.HHCYcanbemild,mod-
erate, or severe elevation of tHcy in blood or serum. Recent
Data expanded the spectrum of the possible pathogenic
implication of HHCY in the course of auto-immune and
vasculitis disease: systemic and retinal vascular occlusive,
thrombogenesis, and so forth.
Several eﬀects induced by HHCY on vascular cells
have been described: diminished nitric oxyde release from
endothelial cells, producing of superoxyde and hydrogen
peroxide,increasedreactiveoxygenspeciesandthromboxane
A2 formation in human platelets, potentiation of low density
lipoprotein oxidation, and stimulation of smooth muscle
cells proliferation.
These features changes coagulation factor so as to
encourage blood clot formation with aggregated platelets
and modiﬁed the adhesive properties of endothelial cells
[24].
Elevated tHcy level has been shown to be a risk of
myocardial infarction [25], stroke [26], and diabetes melitus.
It may also increase the risk of retinal vascular diseases,
such as retinal artery, retinal vein thrombosis, and occlusion
[27, 28].
Our study showed that serum tHcy levels were signif-
icantly higher in whole BD patients than in the healthy
controls, and in active patients. However, no signiﬁcant
diﬀerence was found between tHcy levels and clinical
features.SomestudiesreportedthatHHCYisassociatedwith
BD. These studies are summarized in Table 4.
OthersstudiesreportednormalhomocysteinelevelinBD
patients [14, 29]. Hyperhomocysteinaemia was signiﬁcantly
higher in our male patients. It was found in the studies
of Ates et al. [18] and Feki et al. [23]. These studies areBiochemistry Research International 3
Table 4: Homocysteine and Behc ¸et’s disease.
Author (year) Patients/Controls
Homocysteine
concentration in BD
patients (μmol/L)
Homocysteine
concentration in healthy
(μmol/L)
P
Aksu et al. (2001) [13] 84/36 11.5 ± 5.3 8.8 ± 3.1 <.01
Er et al. (2002) [15] 43/25 15.83 ± 4.44 7.96 ± 6.3 <.001
Korkmaz et al. (2002) [16] 74/35 16.08 ± 7.5 12.9 ± 6.3 <.03
Houman et al. (2003) [17] 59/59 13.3 ± 6.8 10.9 ± 2.4 <.01
Ates et al. (2003) [18] 45/40 11.3 ± 4.3 9.1 ± 2.5 <.01
Yesilova et al. (2004) [19] 32/20 14.86 ± 4.26 10.78 ± 2.28 <.001
Ozdemir et al. (2004) [20] 31/30 14.5 ± 2.6 9.2 ± 2.8 <.0001
Our study (2005) 54/50 18.07 ± 8.9 11.2 ± 6.5 <.01
Sarican et al. (2007) [21] 64/26 11.7 ± 4.6 8.7 ± 2.8 <.01
Ozcan et al. (2007) [22] 23∗/21 12.0 ± 3.3 10.7 ± 2 <.03
∗Active disease.
Table 5: Homocysteine and gender.
Authors (years) Hcy (μmol/L)
Male
Hcy (μmol/L)
Female P
Ates et al. (2003) [18] 12.8 ± 4.5 8.3 ± 1.6 <.001
Feki et al. (2004) [23] 11.5 (7.7−20.6) 9.7 (6.0−15.3) —
Our study (2007) 19.37 ± 7.6 15.69 ± 6.2 .05
summarized in Table 5. Our present results showed that
serum tHcy levels and HHCY were higher in the active
patients than those of the inactive patients and the control
subjects. It was demonstrated by Feki et al. [23], Ates et al.
[18], Sarican et al. [21], and Aksu et al. [13].
Whencorrelatedwithoccularinvolvement,thetHcylevel
were higher but not signiﬁcantly in our BD patients with
retinal vasculitis (21.09 ± 7.8 versus 16.9 ± 6.9μmol/L; P =
.06) and uveitis (20.25 ± 7.8 versus 16.69 ± 6.7μmol/L;
P = .08).
Eretal.[15]foundasigniﬁcantcorrelationbetweentHcy
level and ocular BD (18.25 ± 4.2 versus 13.53 ± 3.34μmol/L;
P = .001); in addition, ocular BD had signiﬁcantly higher
serum endotheline-1 concentrations when compared with
nonocular disease (19.17 ± 5.02 versus 15.6 ± 2.48μmol/L;
P = .003).
Okka et al. [30] showed that tHcy level was signiﬁcantly
higherinBDpatientswithuveitiswhencomparedtoinactive
patients (P = .029). This correlation was found in others
studies [19, 20, 23].
Furthermore, serum tHcy levels among ocular patients
with observed retinal vasoocclusion were signiﬁcantly higher
than ocular patients without such occlusion, suggesting that
thrombogenetic tendency is the main features for Hcy [31].
Aﬂakiandallfoundnosigniﬁcantcorrelationbetweenserum
Hcy level in patients with and without eye involvement
(18.19 ± 9.21 versus 16.59 ± 9.51μmol/L; P = .31) [32].
Relation between retinal vascular occlusive disease and
elevated levels of tHcy was assessed in several studies. Cahill
et al. concluded that elevated tHcy is an independent risk
factor for retinal vascular occlusive disease. In their study
of 87 cases with retinal vascular disease (26 cases of retinal
artery occlusion, 40 cases with central retinal vein occlusion,
and21casesofbranchretinal veinocclusion)comparedwith
87 age matched controls, mean tHcy levels were signiﬁcantly
higher in all disease groups [33].
HHCYisawell-knownriskfactorforthedevelopmentof
thrombosis. The role of HHCY as a contributing risk factor
for thrombosis in BD was investigated in some studies.
Aksu et al. [13] reported that patients with BD and a
histories of thrombosis had signiﬁcantly higher Hcy levels
than those without thrombosis (15.3 ± 6.2 versus 9.3 ±
3.1; P = .0001). Lee et al. [14] suggested that patients with
histories of thrombosis had also signiﬁcantly higher levels of
tHcy. When studying 45 patients with BD, Ates et al. [18]
found that the 29 BD patients with vascular involvement had
a signiﬁcant higher tHcy levels when compared to controls
(P = .001) and nonvascular BD (P<. 01). The same results
were found by Yesilova et al. [19].
No association was found between Hcy levels and
vascular involvement in our BD patients. The same results
were reported by Feki et al. [23] and Korkmaz et al. [16]. In
a recent paper, Ricart et al. [34] found no diﬀerence of Hcy
levels in patients with and without thrombosis.
In the recent study conducted by Durmazlar et al., serum
levels of Hcy in active BD patients with vascular involve-
ment were found signiﬁcantly increased when compared in
patients with active BD without vascular involvement (19 ±
39.25 versus 13.7 ± 26μmol/L; P<. 05). In addition, serum
levels of Hcy in inactive BD with vascular involvement were
foundsigniﬁcantlyincreasedcomparedtoinactiveBD(11.94
± 18 versus 6.43 ± 16μmol/L; P<. 005) [35].
Recently, G¨ on¨ ul et al. found no diﬀerences in tHcy
levels between BD patients, patients with recurrent aphthous
stomatitis, and controls [36].
In our study, we found a signiﬁcant correlation with
tHcy levels and arthritis (P = .05). Yesilova suggested that
tHcy levels may be related to markers of inﬂammation; the
depletion of folate could result from overdemand [19].
Durmazlar et al. found a signiﬁcant positive correlation
between serum Hcy and Tumor Necrosis Factor-α (TNF-α)4 Biochemistry Research International
levels (r = 0.89,P = .00), CRP (r = 0.645,P = .00), and ESR
(r = 0.561, P = .00); Hcy appears to be the best predictor of
TNF-α and positively correlated with inﬂammatory markers.
The mechanism of Hcy associated activation of BD and
endothelial toxicity is not fully understood. It may be in
relation with increased oxidative stress, platelet activation
and atherogenesis by oxidative injury, increased adhesive-
ness, enhanced coagulability, and vascular matrix damage.
Another mechanism is the participation of the oxi-
dant/antioxidant balance; the decreased activity of endothe-
lial derived NO leads to vasoconstriction, platelet aggre-
gation, and monocyte adhesion. A changed in favour of
oxidants occurs, and this imbalance may have a role in the
pathogenesis and/or activity of BD [37].
It has been shown that concentrations of circulating pro-
oxidants and lipid peroxidation products were elevated in
patients with BD [5, 38], although the relationship between
oxidative stress mechanisms and vascular injury in patients
with BD has not been elucidated. It is known that Hcy
generates superoxide and hydrogen peroxide, both of which
havebeenlinkedtoendothelialdamage.Therefore,enhanced
endothelial toxicity caused by elevated tHcy may play an
important role in the pathogenesis in BD, and may cause the
activation of the disease.
A second hypothesis is that Hcy promotes the clotting
cascade via several action; it inhibits the expression and acti-
vation of thrombomodulin, which is a cofactor for protein C
activation, activation of coagulation factor V, and increasing
smooth muscle cells proliferation. It also suppresses the
anticoagulant eﬀect of antithrombin III [39]. An association
with the factor V of Leiden has also been reported.
In conclusion, we demonstrated that serum tHcy levels
are increased in BD and correlated with disease activity.
Because HHCY is a treatable risk factor, measurement and
monitoring of tHcy levels may be valuable index in the
evaluation of patients with BD especially in active stage.
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